Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis

Journal of Research in Medical Sciences

Volumn 17, Issue 10, 2012, Pages 967-974

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^b   Behnava, Bita ^a   Rizzetto, Mario ^c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatitis delta virus large antigen; Infection; Interferons

Indexed keywords

ALPHA2 INTERFERON; INTERFERON; INTERLEUKIN 6; PDFERON B; PEGINTERFERON; PEGINTERFERON 2 ALPHA; PEGINTERFERON 2 BETA; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

CELL HETEROGENEITY; DELTA AGENT HEPATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 84872192376     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Rizzetto M, Verme G. [Delta hepatitis]. Internist (Berl) 1985;26:628-32.
2. Rizzetto M. Hepatitis delta: The virus and the disease. J Hepatol 1990;11 Suppl 1:S145-8.
3. Smedile A, Rizzetto M. HDV: Thirty years later. Dig Liver Dis 2011;43 Suppl 1:S15-8.
4. Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY, et al. Natural history of hepatitis D viral superinfection: Significance of viremia detected by polymerase chain reaction. Gastroenterology 1995;108:796-802.
5. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al., Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000;46:420-6.
6. Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: A meta-analysis of controlled clinical trials. BMC Infect Dis 2011;11:165.
7. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010;70:147-65.
8. Takkenberg RB, Terpstra V, Zaaijer HL, Weegink CJ, Dijkgraaf MG, Jansen PL, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. J Gastroenterol Hepatol 2011; 26:1527-35.
9. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. J Hepatol 2011;55:1121-31.
10. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31.
11. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000;7:428-34.
12. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008;15:314-21.
13. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005;10:721-6.
14. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005;49:1135-8.
15. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006;6:50.
16. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. The First ed. UK: John Wiley and Sons, Ltd; 2009.
17. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. 2 nd ed. New York: Oxford University Press; 2000.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. Farci P, Karayiannis P, Brook MG, Smedile A, Lai ME, Balestrieri A, et al. Treatment of chronic hepatitis delta virus (HDV) infection with human lymphoblastoid alpha interferon. Q J Med 1989;73:1045-54.
20. Marzano A, Ottobrelli A, Spezia C, Daziano E, Soranzo ML, Rizzetto M. Treatment of early chronic delta hepatitis with lyrnphoblastoid alpha interferon: A pilot study. Ital J Gastroenterol 1992;24:119-21.
21. Dalekos GN, Galanakis E, Zervou E, Tzoufi M, Lapatsanis PD, Tsianos EV. Interferon-alpha treatment of children with chronic hepatitis D virus infection: The Greek experience. Hepatogastroenterology 2000;47:1072-6.
22. Hoofnagle J, Mullen K, Peters M, Avigan M, Park Y, Waggoner J, et al. Treatment of chronic delta hepatitis with recombinant human alpha interferon. Prog Clin Biol Res 1987;234:291-8.
23. Yalcin K, Degertekin H, Yildiz F, Akkus Z. A 12-month course of combination therapy with interferon-alfa and lamivudine in patients with chronic hepatitis delta virus: A single-center, prospective, open-label, uncontrolled study. Curr Ther Res 2002;63:736-47.
24. Lau JY, King R, Tibbs CJ, Catterall AP, Smith HM, Portmann BC, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol 1993;39:292-6.
25. Zuberi BF, Quraishy MS, Afsar S, Akhtar N, Kumar A, Dodani SK. Treatment outcome in patients of hepatitis B with hepatitis D: Experience of 4 years at a tertiary care centre in Pakistan. J Coll Physicians Surg Pak 2007;17:320-2.
26. Kokoreva LN, Zmyzgova AV, Shalygina NB, Maksimov SL. The clinico-morphological characteristics and efficacy of interferon therapy in patients with chronic delta hepatitis. Zh Mikrobiol Epidemiol Immunobiol 1994;55-9.
27. Schneider A, Habermehl P, Gerner P, Lausch E, Ballauff A, Wirth S. Alpha-interferon treatment in HBeAg positive children with chronic hepatitis B and associated hepatitis D. Klin Padiatr 1998;210:363-5.
28. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol 1994;44:389-92.
29. Porres JC, Carreno V, Bartolome J, Moreno A, Galiana F, Quiroga JA. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989;9:338-44.
30. Rosina F, Saracco G, Lattore V, Quartarone V, Rizzetto M, Verme G, et al. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Prog Clin Biol Res 1987;234:299-303.
31. Rossetti F, Pontini F, Crivellaro C, Cadrobbi P, Guido M, Pontisso P, et al. Interferon therapy of chronic delta hepatitis in patients cured of pediatric malignancies: Possible harmful effect. Liver 1991;11:255-9.
32. Tocci G, Antonelli L, Boumis E, Colaiacomo M, Guarascio P, Struglia C, et al. Long-term effects of recombinant leukocyte alpha interferon in the treatment of chronic delta hepatitis. Arch Virol Suppl 1992;4:306-7.
33. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005;22:227-32.
34. Buti M, Esteban R, Jardi R, Rodriguez-Frias F, Allende H, Cotrina M, et al. Treatment of chronic type D hepatitis and concomitant human immunodeficiency infection with alpha-interferon. J Hepatol 1992;14:412-3.
35. Ferenci P, Formann E, Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol 2005;100:1626-7.
36. Grattagliano I, Palmieri VO, Portincasa P, Palasciano G. Adefovir dipivoxyl for the treatment of delta-related liver cirrhosis. Ann Pharmacother 2006;40:1681-4.
37. Taillan B, Fuzibet JG, Vinti H, Pesce A, Cassuto JP, Dujardin P. Interferon and delta hepatitis. Ann Intern Med 1988;109:760.
38. Actis GC, Maran E, Rizzetto M. Treatment of patients with delta hepatitis using interferon. Arch Intern Med 1986;146:2081.
39. Taillan B, Fuzibet JG, Pesce A, Vinti H, Gratecos N, Cassuto JP, et al. Treatment of chronic delta hepatitis with recombinant alpha 2 interferon in 8 patients with anti-human immunodeficiency virus antibodies. Presse Med 1988;17:2200.
40. Di Bisceglie AM, Negro F, Smedile A, Bergmann K, Hoofnagle JH. Alpha interferon therapy of chronic delta hepatitis: A pilot study. Prog Clin Biol Res 1991;364:393-7.
41. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-9.
42. Gaudin JL, Trepo C. Therapy of chronic delta hepatitis with alpha-and beta-interferon. Prog Clin Biol Res 1993;382:345-52.
43. Rosina F, Pintus C, Meschievitz C, Rizzetto M. Long term interferon treatment of chronic delta hepatitis: A multicenter Italian study. Prog Clin Biol Res 1991;364:385-91.
44. Di Bisceglie AM, Martin P, Lisker-Melman M, Kassianides C, Korenman J, Bergasa NV, et al. Therapy of chronic delta hepatitis with interferon alfa-2b. J Hepatol 1990;11 Suppl 1:S151-4.
45. Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H, et al. 72 Week Data Of The Hidit-1 Trial: A Multicenter Randomised Study Comparing Peginterferon α-2a Plus Adefovir vs. Peginterferon α-2a Plus Placebo vs. Adefovir in Chronic Delta Hepatitis. J Hepatol 2007;46 (Supplement 1):S4.
46. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728-35.
47. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006;26:805-10.
48. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44:713-20.
49. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: A randomized trial. J Gastroenterol Hepatol 2006;21:657-63.
50. Craxi A, Di Marco V, Volpes R, Marra S, Rizzetto M, Rosina F, et al. Treatment with recombinant alpha 2b-interferon of chronic HDV hepatitis in children. Prog Clin Biol Res 1991;364:399-404.
51. Di Marco V, Giacchino R, Timitilli A, Bortolotti F, Crivellaro C, Calzia R, et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: A multicentre study. J Viral Hepat 1996;3:123-8.
52. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994;330:88-94.
53. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995;15:45-52.
54. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: Utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994;19:1331-6.
55. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology 1991;13:1052-6.
56. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalcin K, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat 2007;14:812-6.